Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014 (2014), Article ID 596312, 12 pages
http://dx.doi.org/10.1155/2014/596312
Research Article

In Vitro and In Vivo Characterization of the New Analgesic Combination Beta-Caryophyllene and Docosahexaenoic Acid

1Department of Medicine, Surgery and Neuroscience, University of Siena, Via Aldo Moro, 53100 Siena, Italy
2Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro, 53100 Siena, Italy

Received 7 February 2014; Accepted 7 April 2014; Published 7 July 2014

Academic Editor: Karl Wah-Keung Tsim

Copyright © 2014 Paolo Fiorenzani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. B. Russo, “Cannabinoids in the management of difficult to treat pain,” Therapeutics and Clinical Risk Management, vol. 4, no. 1, pp. 245–259, 2008. View at Google Scholar · View at Scopus
  2. J. Pergolizzi, A. M. Aloisi, A. Dahan et al., “Current knowledge of buprenorphine and its unique pharmacological profile,” Pain Practice, vol. 10, no. 5, pp. 428–450, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. R. G. Pertwee, “Pharmacology of cannabinoid CB1 and CB2 receptors,” Pharmacology and Therapeutics, vol. 74, no. 2, pp. 129–180, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Mechoulam, E. Fride, and V. Di Marzo, “Endocannabinoids,” European Journal of Pharmacology, vol. 359, no. 1, pp. 1–18, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. O. Ofek, M. Karsak, N. Leclerc et al., “Peripheral cannabinoid receptor, CB2, regulates bone mass,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 3, pp. 696–701, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Galve-Roperh, T. Aguado, D. Rueda, G. Velasco, and M. Guzmán, “Endocannabinoids: a new family of lipid mediators involved in the regulation of neural cell development,” Current Pharmaceutical Design, vol. 12, no. 18, pp. 2319–2325, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Zhang, B. R. Martin, M. W. Adler, R. K. Razdan, J. I. Jallo, and R. F. Tuma, “Cannabinoid CB2 receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model,” Journal of Cerebral Blood Flow and Metabolism, vol. 27, no. 7, pp. 1387–1396, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. X. Ni, E. B. Geller, M. J. Eppihimer, T. K. Eisenstein, M. W. Adler, and R. F. Tuma, “Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model,” Multiple Sclerosis, vol. 10, no. 2, pp. 158–164, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Xu, C. L. Cheng, M. Chen et al., “Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis,” Journal of Leukocyte Biology, vol. 82, no. 3, pp. 532–541, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Walter and N. Stella, “Cannabinoids and neuroinflammation,” The British Journal of Pharmacology, vol. 141, no. 5, pp. 775–785, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. G. A. Cabral and A. Staab, “Effects on the immune system,” in Cannabinoids: Handbook of Experimental Pharmacology, R. G. Pertwee, Ed., pp. 385–423, Springer, Heidelberg, Germany, 2005. View at Google Scholar
  12. J. C. Ashton and E. D. Milligan, “Cannabinoids for the treatment of neuropathic pain: clinical evidence,” Current Opinion in Investigational Drugs, vol. 9, no. 1, pp. 65–75, 2008. View at Google Scholar · View at Scopus
  13. R. D. Hosking and J. P. Zajicek, “Therapeutic potential of cannabis in pain medicine,” British Journal of Anaesthesia, vol. 101, no. 1, pp. 59–68, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Gertsch, M. Leonti, S. Raduner et al., “Beta-caryophyllene is a dietary cannabinoid,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 26, pp. 9099–9104, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Bakır, A. Him, H. Özbek, E. Düz, and M. Tütüncü, “Investigation of the anti-inflammatory and analgesic activities of β-caryophyllene,” International Journal of Essential Oil Therapeutics, vol. 2, pp. 41–44, 2008. View at Google Scholar
  16. A. L. Klauke, I. Racz, B. Pradier et al., “The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain,” European Neuropsychopharmacology, vol. 24, no. 4, pp. 608–620, 2013. View at Publisher · View at Google Scholar
  17. M. J. Zhang and M. Spite, “Resolvins: anti-inflammatory and proresolving mediators derived from omega-3 polyunsaturated fatty acids,” Annual Review of Nutrition, vol. 32, pp. 203–227, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. J. E. Bailes and J. D. Mills, “Docosahexaenoic acid reduces traumatic axonal injury in a rodent head injury model,” Journal of Neurotrauma, vol. 27, no. 9, pp. 1617–1624, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. M. P. Barros, D. P. Marin, A. P. Bolin et al., “Combined astaxanthin and fish oil supplementation improves glutathione-based redox balance in rat plasma and neutrophils,” Chemico-Biological Interactions, vol. 197, no. 1, pp. 58–67, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Zimmermann, “Ethical guidelines for investigations of experimental pain in conscious animals,” Pain, vol. 16, no. 2, pp. 109–110, 1983. View at Publisher · View at Google Scholar · View at Scopus
  21. A. M. Aloisi, I. Ceccarelli, M. Carlucci et al., “Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patients,” Reproductive Biology and Endocrinology, vol. 9, article 26, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. C. de Maddalena, M. Bellini, M. Berra, M. C. Meriggiola, and A. M. Aloisi, “Opioid-induced hypogonadism: why and how to treat it,” Pain Physician, vol. 15, no. 3, pp. ES111–ES118, 2012. View at Google Scholar · View at Scopus
  23. T. P. Malan Jr., M. M. Ibrahim, H. Deng et al., “CB2 cannabinoid receptor-mediated peripheral antinociception,” Pain, vol. 93, no. 3, pp. 239–245, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Hervera, R. Negrete, S. Leánez, J. Martín-Campos, and O. Pol, “The role of nitric oxide in the local antiallodynic and antihyperalgesic effects and expression of δ-opioid and cannabinoid-2 receptors during neuropathic pain in mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 334, no. 3, pp. 887–896, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. M. M. Ibrahim, M. L. Rude, N. J. Stagg et al., “CB2 cannabinoid receptor mediation of antinociception,” Pain, vol. 122, no. 1-2, pp. 36–42, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Hanuš, A. Breuer, S. Tchilibon et al., “HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 25, pp. 14228–14233, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Zimmer, I. Racz, A. L. Klauke, A. Markert, and J. Gertsch, “Beta-caryophyllene , a phytocannabinoid acting on CB2 receptors,” in Proceedings of the 5th IACM Conference on Cannabinoids in Medicine, Cologne, Germany, October 2009.
  28. E. S. Kimball, C. R. Schneider, N. H. Wallace, and P. J. Hornby, “Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium,” American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 291, no. 2, pp. G364–G371, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. G. M. Cole and S. A. Frautschy, “DHA may prevent age-related dementia,” Journal of Nutrition, vol. 140, no. 4, pp. 869–874, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. D. H. Morris, “Methodologic challenges in designing clinical studies to measure differences in the bioequivalence of n-3 fatty acids,” Molecular and Cellular Biochemistry, vol. 246, no. 1-2, pp. 83–90, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. V. Kumar, A. Abbas, and N. Fausto, Robbins and Cotran Pathologic Basis of Disease, W.B. Saunders, Philadelphia, Pa, USA, 2005.
  32. I. Ceccarelli, A. Scaramuzzino, C. Massafra, and A. M. Aloisi, “The behavioral and neuronal effects induced by repetitive nociceptive stimulation are affected by gonadal hormones in male rats,” Pain, vol. 104, no. 1-2, pp. 35–47, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. A. M. Aloisi, I. Ceccarelli, P. Fiorenzani et al., “Aromatase and 5-alpha reductase gene expression: modulation by pain and morphine treatment in male rats,” Molecular Pain, vol. 6, article 69, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Gaumond, P. Arsenault, and S. Marchand, “Specificity of female and male sex hormones on excitatory and inhibitory phases of formalin-induced nociceptive responses,” Brain Research, vol. 1052, no. 1, pp. 105–111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Saghaei, F. Abbaszadeh, K. Naseri et al., “Estradiol attenuates spinal cord injury-induced pain by suppressing microglial activation in thalamic VPL nuclei of rats,” Neuroscience Research, vol. 75, no. 4, pp. 316–323, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. R. R. Ji and M. R. Suter, “p38 MAPK, microglial signaling, and neuropathic pain,” Molecular Pain, vol. 3, article 33, 2007. View at Publisher · View at Google Scholar · View at Scopus